Cigna’s Express Scripts to Remove Humira from Preferred Lists in Favor of Cheaper Biosimilars

Cigna's Decision:
Cigna's Express Scripts will remove AbbVie's Humira from its preferred drug lists in 2025, opting for more affordable biosimilars.

Reason for Change:
The move aims to reduce healthcare costs by preferring cheaper biosimilars like Boehringer Ingelheim's Cyltezo and Teva's Simlandi.

Industry Impact:
This shift signals a significant trend towards cost-effective treatment options, potentially setting a precedent for future drug coverage decisions.

Market Context:
The decision follows a similar move by CVS Health's Caremark and reflects growing competition from biosimilars, which have been impacting AbbVie's revenue.

Broader Implications:
The move highlights the pressure on Pharmacy Benefit Managers (PBMs) to prove their value in reducing healthcare costs, amidst scrutiny from US lawmakers and agencies.